

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P32498C1	PRED. APPLN. NO. 10/168,872
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Robin Edward Buckingham	
		PRED. FILING DATE 04 October 2002	PRED. GROUP 1614

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
Re	5,965,584	10/1999	Ikeda Hitoshi, et al.			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
Re	WO 00/27434	05/2000	PCT				
	0 861 666	09/1998	EPO				
	0 930 076	07/1999	EPO				
	0 306 228	03/1989	EPO				
Re	WO 93/08799	05/1999	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Re	CA	Shimoyama, et al., "Hemodynamic Basis for the Acute Cardiac Effects of Troglitazone in Isolated Perfused Rat Hearts", <i>Diabetes</i> , <u>48</u> (3): 609-615 (1999).
Re	CB	Dagogo-Jack, et al., "Pathophysiology of Type 2 Diabetes and Modes of Action of Therapeutic Inventions", <i>Arch. Int. Med.</i> , <u>157</u> (16): 1802-1817 (1997).
Re	CC	Hosokawa, et al., "Troglitazone Inhibits Bicarbonate Secretion in Rat and Human Duodenum", <i>J. Pharmacol. Exp. Ther.</i> , <u>290</u> (3): 1080-1084 (1999).
EXAMINER <i>Re. Weigden</i>		DATE CONSIDERED <i>10-31-04</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		